Dashboard
Manage Tickers

IFRXInflaRx N.V.

Nasdaq inflarx.de


$ 1.41 $ -0.06 (-4.08 %)    

Wednesday, 21-Aug-2024 15:59:52 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 1.41
$ 1.42 x 100
-- x --
-- - --
$ 1.14 - $ 4.30
64,200
na
83.03M
$ 0.83
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

inflarxs-cash-cash-equivalents-and-marketable-securities-of-746m-is-expected-to-fund-operations-into-2026
InflaRx's Cash, Cash Equivalents And Marke...
08/08/2024 11:36:46

inflarx-q2-2024-gaap-eps-024-misses-020-estimate-sales-6357k-may-not-be-comparable-to-77750k-estimate
InflaRx Q2 2024 GAAP EPS €(0.24) Misses €(...
08/08/2024 11:35:46

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
06/24/2024 17:31:23

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

inflarx-announces-gohibic-vilobelimab-selected-by-barda-for-phase-2-study-on-acute-respiratory-distress-syndrome-one-of-three-investigational-therapies-chosen-by-us-department-of-health-and-human-services
InflaRx Announces GOHIBIC (Vilobelimab) Se...
06/24/2024 12:04:18

DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis St...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
06/06/2024 11:06:47

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
05/09/2024 10:52:12

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

inflarx-q1-2024-gaap-eps-018-beats-022-estimate-sales-39138k-miss-1268m-estimate
InflaRx Q1 2024 GAAP EPS $(0.18) Beats $(0...
05/08/2024 11:34:01

InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.22) by 15...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
03/22/2024 12:22:47

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $8 price target.

inflarxs-inf904-will-initially-target-chronic-spontaneous-urticaria-and-hidradenitis-suppurativa-with-initiation-of-a-phase-2a-pk-dose-ranging-study-expected-by-the-end-of-2024-with-data-availability-anticipated-in-2025
InflaRx's INF904 Will Initially Target Chr...
03/21/2024 11:15:06

inflarx-will-focus-development-activities-and-resources-initially-on-selected-indications-in-immuno-dermatology-with-registrational-phase-vilobelimab-and-inf904
InflaRx Will Focus Development Activities ...
03/21/2024 11:14:33

inflarx-fy-eps-078-down-from-067-yoy-sales-6309k
InflaRx FY EPS €(0.78) Down From €(0.67) Y...
03/21/2024 11:13:03

earnings-scheduled-for-march-21-2024
Earnings Scheduled For March 21, 2024
03/21/2024 10:15:14

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per s...

earnings-preview-inflarx
Earnings Preview: InflaRx
03/20/2024 17:01:53

why-tellurian-shares-are-trading-higher-by-over-16-here-are-20-stocks-moving-premarket
Why Tellurian Shares Are Trading Higher By...
01/26/2024 12:58:39

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hi...

hc-wainwright--co-maintains-buy-on-inflarx-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Infla...
01/25/2024 16:24:00

HC Wainwright & Co. analyst Edward White maintains InflaRx (NASDAQ:IFRX) with a Buy and lowers the price target from $9 ...

inflarx-reports-topline-results-from-multiple-ascending-dose-part-of-its-randomized-double-blind-placebo-controlled-phase-i-trial-for-inf904-to-advance-inf904-into-phase-ii-clinical-development
InflaRx Reports Topline Results From Multi...
01/04/2024 12:03:40

INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the ent...

inflarx-announces-that-the-first-patient-has-been-dosed-in-its-phase-3-study-investigating-the-efficacy-and-safety-of-vilobelimab-in-pyoderma-gangrenosum
InflaRx Announces That The First Patient H...
11/06/2023 12:36:24

why-digitalocean-shares-are-trading-higher-by-around-20-here-are-20-stocks-moving-premarket
Why DigitalOcean Shares Are Trading Higher...
11/03/2023 12:41:43

Gainers Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

raymond-james-maintains-strong-buy-on-inflarx-lowers-price-target-to-19
Raymond James Maintains Strong Buy on Infl...
11/02/2023 16:24:57

Raymond James analyst Steven Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Strong Buy and lowers the price target from $2...

hc-wainwright--co-reiterates-buy-on-inflarx-maintains-9-price-target
HC Wainwright & Co. Reiterates Buy on Infl...
09/12/2023 10:10:59

HC Wainwright & Co. analyst Edward White reiterates InflaRx (NASDAQ:IFRX) with a Buy and maintains $9 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION